Memory Impairment - Pipeline Review, H2 2014

Published: Nov, 2014 | Pages: 52 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Memory Impairment - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Memory Impairment - Pipeline Review, H2 2014', provides an overview of the Memory Impairment's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Memory Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Memory Impairment and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Memory Impairment
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Memory Impairment and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Memory Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Memory Impairment pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Memory Impairment
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Memory Impairment pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Memory Impairment Overview 7
Therapeutics Development 8
Pipeline Products for Memory Impairment - Overview 8
Pipeline Products for Memory Impairment - Comparative Analysis 9
Memory Impairment - Therapeutics under Development by Companies 10
Memory Impairment - Therapeutics under Investigation by Universities/Institutes 11
Memory Impairment - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Memory Impairment - Products under Development by Companies 14
Memory Impairment - Products under Investigation by Universities/Institutes 15
Memory Impairment - Companies Involved in Therapeutics Development 16
Dart NeuroScience LLC 16
M et P Pharma AG 17
Neuren Pharmaceuticals Limited 18
Omeros Corporation 19
Sunovion Pharmaceuticals Inc. 20
Memory Impairment - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
2-PMPA - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
AC-253 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Antisense Oligonucleotide to Inhibit microRNA for Neurology - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
dehydroevodiamine hydrochloride - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Drug for Memory Impairment - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
HT-3951 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
NNZ-2591 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
pregnenolone succinate - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecule 2 to Inhibit PDE4 for Memory Impairment - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Small Molecule to Activate LPL for CNS and Metabolic Disorders - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecule to Inhibit D-amino acid oxidase for Neuropathic Pain, Inflammatory Pain and Memory Impairment - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Small Molecule to Inhibit MAO-B for Memory Impairment - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Small Molecule to Inhibit PDE4 for Memory Impairment - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Small Molecule to Target GPR83 for CNS and Immunological Disorders - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Small Molecules to Activate Carbonic Anhydrase for Learning and Memory Impairment - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Small Molecules to Activate PKC for CNS and Oncology - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Small Molecules to Antagonize GALR3 for Memory Impairment - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Stem Cell Therapy for Memory Impairment and Brain Diseases - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Memory Impairment - Recent Pipeline Updates 49
Memory Impairment - Dormant Projects 50
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 52
Disclaimer 52

List of Tables
Number of Products under Development for Memory Impairment, H2 2014 8
Number of Products under Development for Memory Impairment - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Memory Impairment - Pipeline by Dart NeuroScience LLC, H2 2014 16
Memory Impairment - Pipeline by M et P Pharma AG, H2 2014 17
Memory Impairment - Pipeline by Neuren Pharmaceuticals Limited, H2 2014 18
Memory Impairment - Pipeline by Omeros Corporation, H2 2014 19
Memory Impairment - Pipeline by Sunovion Pharmaceuticals Inc., H2 2014 20
Assessment by Monotherapy Products, H2 2014 21
Number of Products by Stage and Target, H2 2014 23
Number of Products by Stage and Mechanism of Action, H2 2014 25
Number of Products by Stage and Route of Administration, H2 2014 27
Number of Products by Stage and Molecule Type, H2 2014 29
Memory Impairment Therapeutics - Recent Pipeline Updates, H2 2014 49
Memory Impairment - Dormant Projects, H2 2014 50